Description
Researchers have developed a hybrid compound that prevents metronidazole and similar antibiotics from being absorbed by the body before reaching the location of infection, thus avoiding the toxicity associated with higher doses of metronidazole. These hybrid compounds are not only effective in treating C. diff but other bacterial and parasitic infections such as Clostridium perfringen and Helicobacter pylori, and potentially Crohn’s disease and other inflammatory bowel diseases. This technology is being actively marketed by the co-owner, the University of Texas, Arlington.
Keywords
Colostridium Difficile, Chrohn’s, IBS
Granted Patents or Published Applications
Related Scientific References
Licensing Opportunities
Please contact us or UT Arlington (otm@uta.edu) if interested in licensing. Contact: chad.riggs@stjude.org
Related Links
- AdamTS4 Inhibitor for Respiratory Infection (SJ-20-0025)
- BET Bromodomain Inhibitors (SJ-16-0032)
- Biologically Active Ganoderma Lucidum Compounds and Synthesis of Derivatives and Probes (SJ-19-0035)
- Compounds for Treatment of BCR-ABL + Lymphoblastic Leukemias (using an existing malaria drug to overcome resistance) (SJ-11-0042)
- DON and small molecule Bcl-2 family antagonists treating glutamine addicted cell lines for Neuroblastomas and Ewing sarcomas (SJ-13-0026)
- EZHIP(CXorf67)-PRC2 Interaction and Ependymoma (SJ-17-0030)
- Improved Human Carboxylesterase for Therapy with CPT-11 (SJ-06-0006)
- Injectable prodrug of spectinamide as anti-tuberculosis agents (SJ-18-0007)
- MAGE-A11 Inhibitor for cancer (SJ-20-0033)
- Method for Improving Learning and Treating Neurological Diseases (SJ-15-0009)
- Method for treating COVID-19 (SJ-20-0035)
- Methods and compositions for the prevention and treatment of hearing loss using CDK2 inhibitors (SJ-14-0028)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- New Drug Combination for Treating Cytokine Storm Associated With COVID-19 and Other Conditions (SJ-21-0008)
- New Uses for Chloroquine and Chloroquine Analogs (SJ-02-0008 and SJ-05-0017)
- Novel Carboxylesterase Inhibitors (SJ-02-0030)
- P27 Inhibitors for Hearing Regeneration and/or Breast Cancer (SJ-18-0016)
- SARM for Kennedy's Disease (SJ-18-0012)
- SPA70 is a potent antagonist of human pregnane X receptor (PXR Antagonists) (SJ-16-0011)
- Sudemycins: Synthetic Natural Product Analogs as Anti-Cancer Agents (SJ-08-0026 & SJ-13-0007)
- Thalamic microRNA controls the late onset of schizophrenia (SJ-15-0035)
- Therapeutic Leads Targeting Influenza Endonuclease (SJ-09-0041)
- Transcription Factors for Cochlear Hearing Loss Therapy (SJ-17-0016)
- Treating Cochlear Hearing loss with p27Kip1/Atoh1 Combinations (SJ-13-0019)
- Use of Amylase or Maltose to Treat or Prevent Neurodegeneration (SJ-20-0009)
- Use of metabolic drugs to treat influenza infection (SJ-14-0040)
- Use of specific retinoid receptor agonists and antagonists as cancer therapies (SJ-14-0011)
- Use of Ulk1 modulators to treat thalassemia (SJ-18-0004)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.